Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology
TipRanksApr 9 06:17 ET
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
PR NewswireApr 8 16:30 ET
Express News | Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard To Ignore'
Moomoo 24/7Apr 3 10:10 ET
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution
MT NewswiresMar 27 17:30 ET
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
BenzingaMar 26 08:54 ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
Philadelphia, Pennsylvania--(Newsfile Corp. - March 14, 2024) - Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's shareholders. The in
newsfileMar 14 08:15 ET
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
TipRanksMar 11 01:00 ET
A New Cause for Concern: Elevation Oncology, Inc. Adds a New Debt & Financing Risk
TipRanksMar 8 01:02 ET
Elevation Oncology (ELEV) Receives a Buy From TD Cowen
TipRanksMar 7 14:25 ET
Elevation Oncology Price Target Maintained With a $7.00/Share by JMP Securities
Elevation Oncology Price Target Maintained With a $7.00/Share by JMP Securities
Dow JonesMar 7 10:15 ET
Elevation Oncology Is Maintained at Outperform by Wedbush
Elevation Oncology Is Maintained at Outperform by Wedbush
Dow JonesMar 7 08:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
Moomoo 24/7Mar 7 07:40 ET
Elevation Oncology: A Strong Buy on Robust Financials and Promising Clinical Pipeline
TipRanksMar 7 06:26 ET
Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)
TipRanksMar 7 00:30 ET
Top 10 Best Performing Biotech Stocks of 2024 so Far
Seeking AlphaMar 6 11:25 ET
Elevation Oncology GAAP EPS of -$0.19
Seeking AlphaMar 6 10:00 ET
Elevation Oncology, Inc. Q4 Loss Decreases, Beats Estimates
RTTNewsMar 6 08:03 ET
Express News | Elevation Oncology Q4 EPS $(0.19) Beats $(0.23) Estimate; Cash, Cash Equivalents And Marketable Securities And Approximately $17M In Net Proceeds Raised Under Its ATM Facility Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Moomoo 24/7Mar 6 07:36 ET
Elevation Oncology 4Q Loss $45.7M >ELEV
Elevation Oncology 4Q Loss $45.7M >ELEV
Dow JonesMar 6 07:31 ET
Elevation Oncology Had Cash, Cash Equivalents and Marketable Securities Totaling $83.1M at Dec 31 >ELEV
Elevation Oncology Had Cash, Cash Equivalents and Marketable Securities Totaling $83.1M at Dec 31 >ELEV
Dow JonesMar 6 07:31 ET
No Data
No Data